Therapy Areas: Respiratory
CStone doses first cancer patient with anti-CTLA-4 antibody CS1002 as part of its Phase I study in Australia
4 May 2018 -

Biopharmaceutical company CStone Pharmaceuticals (Suzhou) Co Ltd reported on Thursday the start of treatment of the first cancer patient with CS1002 under a Phase I clinical trial in Australia.

CS1002 is the company's investigational drug targeting cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and also the first drug candidate that has entered clinical trials outside of China. CS1002 is an immunoglobulin G1 (IgG1), fully-human monoclonal antibody against CTLA-4.

The company said the CTLA-4 pathway takes effect during the early stage of immune response prior to the PD-1 checkpoint, occurring in the lymph nodes when CTLA-4 on activated T cells binds to its ligands B7-1 (CD80) or B7-2 (CD86) on tumor cells.A blockade of immune checkpoints using antibody drugs has been shown to promote T cell activation and proliferation, as well as stimulate the generation of memory T cells leading to durable anti-tumor response.

In conjunction, the company owns all global rights to CS1002 and intends to develop for the treatment of melanoma, non-small cell lung cancer, renal carcinoma as well as other solid tumors.

This Phase I study is being led by Professor Dusan Kotasek of the Ashford Cancer Centre Research and will assess CS1002's safety, tolerability, pharmacokinetics and initial efficacy in patients with advanced solid tumors.